Novo Nordisk’s Big Reset: What 9,000 Job Cuts Signal for Pharma’s Future

The pharma giant Novo Nordisk is making headlines — and not for launching another blockbuster. Instead, it has announced a major restructuring that will slash 9,000 jobs, about 11.5% of its workforce, as it recalibrates to face intensifying competition in the weight-loss and diabetes space.

This is more than a workforce story. It’s a signal to the entire pharmaceutical ecosystem about what happens when a runaway success meets market reality.